Del Conte, G
Sessa, C
von Moos, R
ViganĂ², L
Digena, T
Locatelli, A
Gallerani, E
Fasolo, A
Tessari, A
Cathomas, R
Gianni, L
Article History
Received: 27 January 2014
Revised: 29 April 2014
Accepted: 27 May 2014
First Online: 15 July 2014
Competing interests
: Advisory/consulting roles have been held by RVM for Amgen, GlaxoSmithKline, Novartis, Merck Sharp & Dohme and Bristol-Myers Squibb; by CS and RC for AstraZeneca; and by LG for Roche, Genentech, GlaxoSmithKline, Novartis, Pfizer, Boehringer Ingelheim, Celgene and Tahio Pharmaceutical. No potential conflict of interest were disclosed by the other authors.